It's not often you can find things with genuine 100 bagger...

It's not often you can find things with genuine 100 bagger potential that are already in phase 3, with a couple of shots on goal - fsgs and dkd.

Big pharma looks at 2 things with smaller biotech players: the data and the revenue opportunities. DXB has good data to date (interim results will be obviously key here) and clearly the revenue opportunities are large, now multi billion per annum and growing in an area where there's a clear unmet need.

Also you would think big pharma may want to lock in DXB earlier than ordinarily because of the potential to combine with their ARBs and therefore extending those patents.